Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review

BackgroundImmune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have shown impressive therapeutic results. However, only 20–40% of advanced melanoma patients have durable responses to ICI, and these positive effects must be balanced against severe off-target immune toxicity and hi...

Full description

Bibliographic Details
Main Authors: Charissa A. C. Jessurun, Julien A. M. Vos, Jacqueline Limpens, Rosalie M. Luiten
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-09-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitors
predictive biomarkers
melanoma
immune response
PD-1
PD-L1
Online Access:http://journal.frontiersin.org/article/10.3389/fonc.2017.00233/full

Internet

http://journal.frontiersin.org/article/10.3389/fonc.2017.00233/full

Similar Items